Diagnosing Campylobacter: Stool Culture, PCR, and When to Test

Most people with Campylobacter food poisoning recover without ever getting a lab test — and that is often the right approach. But knowing when testing matters, what tests your doctor should order, and how to give the lab its best shot at finding the bacteria can make a real difference for anyone with a severe or complicated illness. This guide explains each diagnostic tool in plain language so you can have an informed conversation with your healthcare team.

  1. When to Test — and When Not To
  2. Stool Culture: The Traditional Gold Standard
  3. PCR Multiplex Gastrointestinal Panels
  4. Identifying the Species: C. jejuni vs C. coli
  5. Antibiotic Susceptibility Testing
  6. Blood Cultures: When Infection Spreads Beyond the Gut
  7. Serology for Guillain-Barré Workup
  8. Practical Advice for Patients
  9. Key Research Papers
  10. Connections
  11. Featured Videos

When to Test — and When Not To

The vast majority of Campylobacter cases are mild to moderate diarrheal illnesses that resolve on their own within a week. For these patients, sending a stool sample to the lab rarely changes how the doctor treats them — the illness will be over before results come back, and most healthy adults do not need antibiotics anyway. Testing in low-risk, mild cases adds cost and lab time without benefit.

Testing is clearly indicated in these situations:

For mild illness in an otherwise healthy adult — loose stools for three to five days without blood, without high fever, and improving — watchful waiting with fluids and rest is entirely appropriate. No test needed.

Stool Culture: The Traditional Gold Standard

For decades, stool culture was the only way to confirm Campylobacter infection. It remains important because it is the only method that yields a live organism for antibiotic susceptibility testing — critical given rising resistance to fluoroquinolones and macrolides.

Campylobacter is finicky. It cannot simply be dropped into a standard culture incubator and left overnight. Three specific conditions must be met:

  1. Microaerophilic atmosphere — Campylobacter requires reduced oxygen: approximately 5% O2, 10% CO2, and 85% N2. It cannot grow in normal room air (21% O2), nor in fully anaerobic conditions. Laboratories use special gas-generating envelopes or tri-gas incubators to create this narrow window.
  2. Thermophilic incubation at 42 °C — unlike most pathogens incubated at standard body temperature (37 °C), Campylobacter grows best at 42 °C, which reflects the body temperature of poultry (its primary animal reservoir). This elevated temperature also suppresses the growth of most human fecal bacteria that would otherwise outcompete Campylobacter on the plate.
  3. Selective media — Skirrow medium (blood agar with vancomycin, polymyxin B, and trimethoprim) and CCDA (charcoal-cefoperazone-deoxycholate agar) are the most common formulations. These suppress competing fecal flora while allowing Campylobacter to grow.

Results take 48 to 72 hours from when the sample arrives at the lab. A critical practical point: Campylobacter dies quickly outside the body. Stool should be delivered to the lab within two hours at room temperature, or within 24 hours if refrigerated. Special transport media (such as Cary-Blair) extend viability but do not compensate for prolonged delays. Sensitivity of culture drops sharply after the first three to four days of illness as bacterial shedding declines, and further after antibiotics are started.

Culture sensitivity ranges from 60–90% depending on lab technique and sample freshness, which is why PCR panels have gained ground in recent years.

PCR Multiplex Gastrointestinal Panels

Syndromic molecular panels — such as the BioFire FilmArray GI Panel, ePlex GI Pathogen Panel, and BD MAX Enteric Bacterial Panel — have transformed how infectious diarrhea is diagnosed in hospitals and large clinic systems. A single stool swab is loaded into the cartridge, and within one to two hours the machine reports on up to 22 pathogens simultaneously: bacterial (Campylobacter, Salmonella, Shigella, Yersinia, E. coli O157, STEC, C. diff), viral (norovirus, rotavirus, astrovirus, adenovirus), and parasitic (Cryptosporidium, Giardia).

Performance for Campylobacter is excellent. Sensitivity and specificity both exceed 95%, consistently outperforming culture in clinical studies. The test detects bacterial DNA even when viable organisms are no longer present — meaning it works a day or two later into the illness when culture yield has fallen. It is also unaffected by whether the patient has started antibiotics.

However, PCR panels have a critical limitation: they tell you the bacterium is there, but they cannot tell you which antibiotics will kill it. For a healthy young adult with Campylobacter gastroenteritis who does not need antibiotics, this is not a problem. But for an immunocompromised patient, an elderly person with severe illness, or anyone who needs treatment, a positive PCR result should prompt the clinician to also send stool for culture so susceptibility testing can be performed.

Cost is higher than traditional culture, and insurance coverage varies. Panels are now the default in many US academic medical centers and are becoming standard in community hospitals, particularly for admitted patients.

Identifying the Species: C. jejuni vs C. coli

Most clinical laboratories and PCR panels report a positive result as "Campylobacter spp." without specifying whether it is C. jejuni or C. coli. For routine clinical care, this is usually sufficient. The two species cause clinically identical illness, and management is the same for most patients.

Species identification matters most when antibiotic treatment is being planned or when resistance surveillance is being conducted. C. coli has higher rates of macrolide (azithromycin) resistance than C. jejuni in many parts of the world — a meaningful distinction if azithromycin is being considered for treatment.

The traditional biochemical method is the hippurate hydrolysis test: C. jejuni hydrolyzes hippurate (positive test); C. coli does not (negative). This is simple and reliable but requires that a culture isolate be available. MALDI-TOF mass spectrometry — now standard in most reference and large clinical laboratories — can identify species from a culture colony in minutes. Whole-genome sequencing is used at public health and reference laboratories for outbreak strain typing.

If you are a patient, you do not need to worry about species identification unless your doctor mentions it in the context of treatment decisions. The clinician will order the appropriate follow-up if it is needed.

Antibiotic Susceptibility Testing

Knowing that someone has Campylobacter is not the same as knowing which antibiotic will work. Antibiotic resistance in Campylobacter has risen dramatically over the past two decades, making susceptibility testing an important part of managing severe or refractory illness.

Fluoroquinolone resistance (ciprofloxacin) now exceeds 50% in many countries and is 60–80% in parts of Asia, Southeast Asia, and Latin America. In the United States, resistance rates vary by region and source country of the infection but have been steadily rising. Macrolide resistance (azithromycin, erythromycin) remains lower — typically 5–10% in the US and Europe — but is increasing, particularly in C. coli.

Susceptibility testing requires a live culture isolate. The most common methods are disk diffusion (placing antibiotic-impregnated paper disks on a bacterial lawn and measuring inhibition zones) and E-test (gradient strips that provide a minimum inhibitory concentration). Results for Campylobacter typically take 24–48 hours after the initial culture is positive — so you are looking at 72–96 hours from sample collection to susceptibility result.

For most outpatient cases — mild to moderate illness in a healthy adult — waiting four days for susceptibility results is not practical, and antibiotics are often not needed in the first place. Susceptibility testing is most valuable in: patients who have failed initial antibiotic therapy; severely ill hospitalized patients in whom the right drug matters from day one; immunocompromised patients where any Campylobacter infection is treated regardless of severity; and public health surveillance to track resistance trends.

Blood Cultures: When Infection Spreads Beyond the Gut

Campylobacter occasionally escapes the intestine and enters the bloodstream — a condition called bacteremia. In immunocompetent adults, this is rare, estimated at less than 1% of all Campylobacter gastroenteritis cases. In certain high-risk groups, it is significantly more common and carries real mortality risk.

Blood cultures should be drawn when:

A note on species: bacteremia is much more common with Campylobacter fetus (a different species from C. jejuni) and is associated with vascular infections. C. jejuni bacteremia occurs but is less common. A positive blood culture is always an indication to treat with antibiotics, with a longer course (typically 10–14 days) than is used for uncomplicated gastroenteritis.

Serology for Guillain-Barré Workup

Guillain-Barré syndrome (GBS) is a rare but serious autoimmune nerve disease. In roughly 25–40% of GBS cases, the preceding trigger is Campylobacter gastroenteritis — often a diarrheal illness that occurred one to three weeks before the neurological symptoms began. By the time GBS is diagnosed, the diarrhea is usually long over and stool culture or PCR is no longer useful.

Serological testing at reference or academic medical center labs can confirm prior Campylobacter infection:

These serological tests are not used for routine food poisoning diagnosis — they are research and specialist tools. For a patient with GBS being evaluated at a neurology center, the neurologist will typically order a cerebrospinal fluid (CSF) analysis (looking for the characteristic pattern of high protein with normal cell count, called cytoalbuminous dissociation) and nerve conduction studies, which define the subtype of GBS and guide treatment with IVIG or plasmapheresis. The Campylobacter serology helps confirm the causal link but does not change GBS treatment.

Practical Advice for Patients

When to call the doctor versus wait it out

Seek medical attention promptly if you have: blood in your stool; a fever above 38.5 °C (101 °F); signs of dehydration (extreme thirst, no urination for eight or more hours, dizziness on standing); symptoms that are not improving after five to seven days; or any neurological symptoms starting one to three weeks after diarrhea (weakness in the legs, tingling in the hands and feet, difficulty walking).

For mild diarrhea without blood and without high fever in an otherwise healthy adult: rest, fluids (oral rehydration solution is better than plain water), and time. You do not need to call the doctor on day one of loose stools.

What to tell your doctor to get the right tests ordered

Be specific about: when symptoms started; whether there is blood in the stool; the severity of fever; whether you recently ate undercooked poultry, unpasteurized dairy, or food from a place others have also gotten sick; and whether you are immunocompromised, pregnant, elderly, or a healthcare or food service worker. Mentioning "I ate chicken at a restaurant three days before this started and two other people got sick too" immediately flags the need for a stool culture and possibly a multiplex PCR panel.

How to collect a stool sample correctly

Your doctor or lab will provide a sterile container. Key points:

Rectal swabs are an alternative when a stool sample cannot be obtained — for example, in young children or very ill patients who cannot produce a sample on demand. Yield is lower than from a stool sample but acceptable in these circumstances.

Testing after three to four days of illness reduces the chance of finding the organism — bacterial shedding declines over time. If you need a confirmed diagnosis (for work return, outbreak investigation, or because your doctor is considering treatment), get to the lab quickly.

Key Research Papers

  1. Engberg J, Aarestrup FM, Taylor DE, Gerner-Smidt P, Nachamkin I. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis. 2001;7(1):24–34. PMID 11266290
  2. Rohner P, Pittet D, Pepey B, Nije-Njike B, Auckenthaler R. Evaluation of the FilmArray gastrointestinal panel for the detection of enteropathogenic bacteria, viruses, and parasites in a setting with a high prevalence of parasitosis. J Clin Microbiol. 2016;54(5):1205–9. PMID 26888901
  3. Bessède E, Delcamp A, Sifré E, Buissonnière A, Mégraud F. New methods for detection of campylobacters with increased sensitivity in human stools. J Clin Microbiol. 2011;49(5):1646–50. PMID 21325557
  4. Humphries RM, Linscott AJ. Practical guidance for clinical microbiology laboratories: diagnosis of bacterial gastroenteritis. Clin Microbiol Rev. 2015;28(1):3–31. PMID 25567220
  5. Kaakoush NO, Castaño-Rodríguez N, Mitchell HM, Man SM. Global epidemiology of Campylobacter infection. Clin Microbiol Rev. 2015;28(3):687–720. PMID 25999046
  6. Nachamkin I, Allos BM, Ho T. Campylobacter species and Guillain-Barré syndrome. Clin Microbiol Rev. 1998;11(3):555–67. PMID 9665983
  7. Allos BM. Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis. 2001;32(8):1201–6. PMID 11303253
  8. Wieczorek K, Osek J. Antimicrobial resistance mechanisms among Campylobacter. Biomed Res Int. 2013;2013:340605. PMID 23844363
  9. Couturier BA, Couturier MR, Kalp KJ, Fisher MA. Detection of non-jejuni and -coli Campylobacter species from stool specimens with an immunochromatographic antigen detection test. J Clin Microbiol. 2013;51(4):1143–7. See also Couturier BA et al. Evaluation of the BD MAX enteric bacterial panel for detection of Salmonella spp., Campylobacter spp. (C. jejuni and C. coli), Shiga toxin 1 and 2, and Escherichia coli O157 in clinical stool specimens. J Clin Microbiol. 2013;51(12):4067–72. PMID 24108614
  10. Jacobs BC, Rothbarth PH, van der Meché FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology. 1998;51(4):1110–5. PMID 9781538

PubMed searches for further reading:

  1. Campylobacter stool culture diagnosis
  2. Multiplex PCR gastrointestinal panel Campylobacter
  3. Campylobacter antimicrobial susceptibility testing
  4. Campylobacter bacteremia immunocompromised
  5. Guillain-Barré syndrome Campylobacter serology anti-ganglioside

Back to Table of Contents

Connections

Back to Table of Contents